

TCR, also develop spontaneous uveitis [22,23,44]. However, some findings in these mice must be interpreted with caution, because responses may be affected by integration effects, by the level of expression and tissue distribution of the neo-self Ag and by the affinity of the specific TCR, and therefore may be quite different from responses to the native Ag. Thus, the R161 TCR transgenic mice offer some specific advantages over the previously available models that make them attractive for particular types of studies, e.g., study of natural triggers of uveitis or cell migration, under “amplified” conditions.

In conclusion, TCR transgenic mice specific to native self-antigens are available for only a few autoimmune disease models, namely, type 1 diabetes [13,14], experimental autoimmune gastritis [15,16] and experimental autoimmune encephalomyelitis [17–21]. There is no doubt that they have contributed tremendously to unraveling the basic mechanisms involved in the pathogenesis of the diseases represented by these models. It is of note that some of them develop autoimmune diseases spontaneously under certain environmental conditions (e.g. “dirty” housing) and/or genetic backgrounds (crossed to a specific MHC, or in a lymphopenic situation). Our new model of spontaneous uveitis in R161 TCR Tg mice now joins these other disease models as a valuable tool to study the pathogenesis of potentially blinding uveitic diseases.

## Acknowledgment

We thank NEI Genetic Engineering Core for microinjection of TCR transgenic constructs and assistance in maintaining the Tg mouse colonies, NEI Histology Core for processing the slides and NEI Flow Cytometry Core for assistances in cell sorting and analysis. We are grateful to Drs. Hidehiro Yamane and William E. Paul for critical reading of the manuscript. This work was supported by NEI intramural funding, project # EY000184.

## Appendix A. Supplementary data

Supplementary data related to this article can be found online at <http://dx.doi.org/10.1016/j.jaut.2013.06.003>.

**Supplementary Table 1**

V $\alpha$  and V $\beta$  primer sequences used in this study.

V $\alpha$	Primer sequence (5' -> 3')	V $\beta$	Primer sequence (5' -> 3')
1	GCACTGATGCCATCTCTC	1	CTGAATGCCAGACAGCTCCAAGC
2	AAAGGGAGAAAAAGCTCTCC	2	TCACTGATCAGGAGCTGAGGC
3	AACTACTATCCGGAGACCC	3.1	CCTTGACGGCTAAATTCACTG
4	CACTATCCGGAGAACGTC	4	GCCTCAAGTCCTCACCAAACCTC
5	CAAGAAAGACAAACGACTCTC	5.1	CATTATGATAAAATGGAGAGAT
6	ATGGCTTCTCGGTATTGCC	5.2	AAGGTTGGAGAGAGACAAAGGATTC
7	TCTGTACTCTCCAGAACATC	6	CTCTCACTGTGACATCTGCC
8	CAACAAAGGAGCCGACCC	7	TACAGGTCTCACCGAAGAAC
9	TAGTGAAGTCTGGTGTGTC	8.1	CATTACTCATATGTCGTCAC
10	AACTCGCAGCTTTCGAC	8.2	CATTATTCTATGTCGTCGG
11	CCCTGCACATCAGGGATGCC	8.3	TGCTGGCAACCTCGAATAGGA
12	TCTGTTATCTCTGTCGACC	9	TCTCTCTACATTGGCTCTGCCAGGC
13	TGAGGCGGAGTTAGGAAGA	10	ATCAAGTCTGAGACCCGGAGGA
14	GAGTCTCAGTCTGGTGTG	11	GCACTCAACTCTGAAGATCCAGAGC
15	AACGATTCTCCCTGACATC	12	GATGGTGGGGCTTCAGGATC
16	CTGTACTGAGACCCCTCC	13	AGGCCTAAAGGAACTAACCTCCAC
17	TTCCATCGGACTCATCATCA	14	ACGACCAATTCTACCTAACGAC
18	AGAACGCCAGTGGAAAGACTC	15	CCCACTAGTCATCCAACTTATCC
19	TGCCCTCATACCTCTGTGTC	16	CACTCTGAAATCCAAACCCAC
20	TTCTCACTGCACATCACAGC	17	AGTGTTCCTCGAACATCACAG
		18	CAGCCGCCAACCTAACATTCTC
		19	CTGCTAAGAACCATGTACCA
		20	TCTGCAGCTGGAAATCAGAA
C $\alpha$	TGGCGTIGGTCTTTGAAG	C $\beta$	CTTGGTGGAGTCACATTCTC

V $\alpha$ 1-12 and C $\alpha$  from Casanova et al. [31], V $\alpha$ 13-20 from DiRenzo et al. [32], and V $\beta$ 1-20 from Pannetier et al. [33].

## References

- [1] Streilein JW. Ocular immune privilege: the eye takes a dim but practical view of immunity and inflammation. *J Leukoc Biol* 2003;74:179–85.
- [2] Caspi RR. Ocular autoimmunity: the price of privilege? *Immunol Rev* 2006;213:23–35.
- [3] Nussenblatt RB, Whitcup SM. Uveitis: fundamentals and clinical practice. 3rd ed. Philadelphia, PA: Elsevier; 2004. Mosby.
- [4] Gritz DC, Wong IG. Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study. *Ophthalmology* 2004;111:491–500.
- [5] Durrani OM, Meads CA, Murray PI. Uveitis: a potentially blinding disease. *Ophthalmologica* 2004;218:223–36.
- [6] Yamamoto JH, Minami M, Inaba G, Masuda K, Mochizuki M. Cellular autoimmunity to retinal specific antigens in patients with Behcet's disease. *Br J Ophthalmol* 1993;77:584–9.
- [7] Gery I, Nussenblatt RB, Chan CC, Caspi RR. Autoimmune diseases of the eye. In: Theophilopoulos AN, Bona CA, editors. *The molecular pathology of autoimmune diseases*. New York, NY: Taylor and Francis; 2002.
- [8] Descamps FJ, Kangave D, Cauwe B, Martens E, Geboes K, Abu El-Asrar A, et al. Interphotoreceptor retinoid-binding protein as biomarker in systemic autoimmunity with eye inflections. *J Cell Mol Med* 2008;12:2449–56.
- [9] Takeuchi M, Usui Y, Okunuki Y, Zhang L, Ma J, Yamakawa N, et al. Immune responses to interphotoreceptor retinoid-binding protein and S-antigen in Behcet's patients with uveitis. *Invest Ophthalmol Vis Sci* 2010;51:3067–75.
- [10] de Smet MD, Yamamoto JH, Mochizuki M, Gery I, Singh VK, Shinohara T, et al. Cellular immune responses of patients with uveitis to retinal antigens and their fragments. *Am J Ophthalmol* 1990;110:135–42.
- [11] Horai R, Caspi RR. Retinal inflammation: uveitis/uveoretinitis. Animal models for retinal diseases neuromethods. SpringerLink; 2010. p. 207–25.
- [12] Pennesi G, Mattapallil MJ, Sun SH, Avichezer D, Silver PB, Karabekian Z, et al. A humanized model of experimental autoimmune uveitis in HLA class II transgenic mice. *J Clin Invest* 2003;111:1171–80.
- [13] Verdaguera J, Schmidt D, Amrani A, Anderson B, Averill N, Santamaría P. Spontaneous autoimmune diabetes in monoclonal T cell nonobese diabetic mice. *J Exp Med* 1997;186:1663–76.
- [14] Verdaguera J, Yoon JW, Anderson B, Averill N, Utsugi T, Park BJ, et al. Acceleration of spontaneous diabetes in TCR-beta-transgenic nonobese diabetic mice by beta-cell cytotoxic CD8+ T cells expressing identical endogenous TCR-alpha chains. *J Immunol* 1996;157:4726–35.
- [15] Alderuccio F, Cataldo V, van Driel IR, Gleeson PA, Toh BH. Tolerance and autoimmunity to a gastritogenic peptide in TCR transgenic mice. *Int Immunol* 2000;12:343–52.
- [16] McHugh RS, Shevach EM, Margulies DH, Natarajan KA. T cell receptor transgenic model of severe, spontaneous organ-specific autoimmunity. *Eur J Immunol* 2001;31:2094–103.
- [17] Goverman J, Woods A, Larson L, Weiner LP, Hood L, Zaller DM. Transgenic mice that express a myelin basic protein-specific T cell receptor develop spontaneous autoimmunity. *Cell* 1993;72:551–60.
- [18] Lafaille JJ, Nagashima K, Katsuki M, Tonegawa S. High incidence of spontaneous autoimmune encephalomyelitis in immunodeficient anti-myelin basic protein T cell receptor transgenic mice. *Cell* 1994;78:399–408.
- [19] Waldner H, Whitters MJ, Sobel RA, Collins M, Kuchroo VK. Fulminant spontaneous autoimmunity of the central nervous system in mice transgenic for the myelin proteolipid protein-specific T cell receptor. *Proc Natl Acad Sci U S A* 2000;97:3412–7.
- [20] Bettelli E, Pagany M, Weiner HL, Linington C, Sobel RA, Kuchroo VK. Myelin oligodendrocyte glycoprotein-specific T cell receptor transgenic mice develop spontaneous autoimmune optic neuritis. *J Exp Med* 2003;197:1073–81.
- [21] Pollinger B, Krishnamoorthy G, Berer K, Lassmann H, Bosl MR, Dunn R, et al. Spontaneous relapsing-remitting EAE in the SJL/J mouse: MOG-reactive transgenic T cells recruit endogenous MOG-specific B cells. *J Exp Med* 2009;206:1303–16.
- [22] Lambe T, Leung JC, Ferry H, Bouriez-Jones T, Makinen K, Crockford TL, et al. Limited peripheral T cell energy predisposes to retinal autoimmunity. *J Immunol* 2007;178:4276–83.
- [23] Ham DI, Kim SJ, Chen J, Vistica BP, Fariss RN, Lee RS, et al. Central immunotolerance in transgenic mice expressing a foreign antigen under control of the rhodopsin promoter. *Invest Ophthalmol Vis Sci* 2004;45:857–62.
- [24] Gregerson DS, Torseth JW, McPherson SW, Roberts JP, Shinohara T, Zack DJ. Retinal expression of a neo-self antigen, beta-galactosidase, is not tolerogenic and creates a target for autoimmune uveoretinitis. *J Immunol* 1999;163:1073–80.
- [25] McPherson SW, Heuss ND, Gregerson DS. Lymphopenia-induced proliferation is a potent activator for CD4+ T cell-mediated autoimmune disease in the retina. *J Immunol* 2009;182:969–79.
- [26] Silver PB, Rizzo LV, Chan CC, Donoso LA, Wiggert B, Caspi RR. Identification of a major pathogenic epitope in the human IRBP molecule recognized by mice of the H-2r haplotype. *Invest Ophthalmol Vis Sci* 1995;36:946–54.
- [27] Letourneau F, Malissen B. Derivation of a T cell hybridoma variant deprived of functional T cell receptor alpha and beta chain transcripts reveals a nonfunctional alpha-mRNA of BW5147 origin. *Eur J Immunol* 1989;19:2269–74.
- [28] Zhumabekov T, Corbella P, Tolaini M, Kioussis D. Improved version of a human CD2 minigene based vector for T cell-specific expression in transgenic mice. *J Immunol Methods* 1995;185:133–40.